{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:36:38Z","timestamp":1793673398043,"version":"4.5.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32460138"],"award-info":[{"award-number":["32460138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470609"],"award-info":[{"award-number":["32470609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070626"],"award-info":[{"award-number":["32070626"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171262"],"award-info":[{"award-number":["32171262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32570663"],"award-info":[{"award-number":["32570663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32560140"],"award-info":[{"award-number":["32560140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103038","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:30:05Z","timestamp":1785195005000},"page":"103038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["An antisense oligonucleotide targeting STK25 as a long-acting therapeutic candidate for early MASLD"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-6556","authenticated-orcid":false,"given":"Ao","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiping","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunkai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aomei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2411-3965","authenticated-orcid":false,"given":"Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-0271","authenticated-orcid":false,"given":"Yunkun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103038_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2026.103038_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.omtn.2026.103038_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.103038_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jceh.2019.07.002","article-title":"Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies","volume":"10","author":"Reddy","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.omtn.2026.103038_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103038_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2337\/dc12-0033","article-title":"Liver Fat Is Reduced by an Isoenergetic MUFA Diet in a Controlled Randomized Study in Type 2 Diabetic Patients","volume":"35","author":"Bozzetto","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.omtn.2026.103038_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib13","first-page":"6","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"GROUP","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103038_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.777131","article-title":"Statins in Non-alcoholic Steatohepatitis","volume":"8","author":"Torres-Pe\u00f1a","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.omtn.2026.103038_bib15","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103038_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102377","article-title":"Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics","volume":"48","author":"Alshehade","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.omtn.2026.103038_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70242-8","article-title":"Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-\u03b2 agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta analysis","volume":"14","author":"Suvarna","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103038_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2026.103038_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011320","article-title":"Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study","volume":"8","author":"Ko","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.omtn.2026.103038_bib20","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.omtn.2026.103038_bib21","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103038_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jval.2015.06.002","article-title":"Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland","volume":"18","author":"Rannanheimo","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.omtn.2026.103038_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/fampra\/cms046","article-title":"Physician patient communication failure facilitates medication errors in older polymedicated patients with multiple comorbidities","volume":"30","author":"Mira","year":"2013","journal-title":"Fam. Pract."},{"key":"10.1016\/j.omtn.2026.103038_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of Antisense Drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2026.103038_bib25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.103038_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.omtn.2026.103038_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","article-title":"Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.103038_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense Drugs Make Sense for Neurological Diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2026.103038_bib29","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103038_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103038_bib31","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.103038_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103038_bib33","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1096\/fj.14-264937","article-title":"Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH","volume":"29","author":"Amrutkar","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103038_bib34","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1096\/fj.201600562R","article-title":"STK25 is a critical determinant in nonalcoholic steatohepatitis","volume":"30","author":"Amrutkar","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103038_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cellbi.2009.06.011","article-title":"Lipid droplets interact with mitochondria using SNAP23","volume":"33","author":"J\u00e4gerstr\u00f6m","year":"2009","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.omtn.2026.103038_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1194\/jlr.RA119000316","article-title":"Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver","volume":"61","author":"Nerstedt","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtn.2026.103038_bib37","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00125-012-2511-7","article-title":"Serine\/threonine protein kinase 25 (STK25): a novel negative regulator of lipid and glucose metabolism in rodent and human skeletal muscle","volume":"55","author":"Nerstedt","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2026.103038_bib38","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1096\/fj.13-228494","article-title":"Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high-fat diet","volume":"27","author":"Cansby","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2026.103038_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/JOE-18-0182","article-title":"STK25 regulates oxidative capacity and metabolic efficiency in adipose tissue","volume":"238","author":"S\u00fctt","year":"2018","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.omtn.2026.103038_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hep4.1128","article-title":"Serine\/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice","volume":"2","author":"Nu\u00f1ez-Dur\u00e1n","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.omtn.2026.103038_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcmgh.2018.12.004","article-title":"Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease","volume":"7","author":"Cansby","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtn.2026.103038_bib42","doi-asserted-by":"crossref","first-page":"D925","DOI":"10.1093\/nar\/gkae977","article-title":"The evolution of dbSNP: 25 years of impact in genomic research","volume":"53","author":"Phan","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103038_bib43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting \u2014 Strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103038_bib44","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ymthe.2019.06.009","article-title":"Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models","volume":"27","author":"Kim","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103038_bib45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.omtn.2026.103038_bib46","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/ijms24065843","article-title":"Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-\u03baB Signaling Pathways in an RGS5-Dependent Manner","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103038_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.103038_bib48","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2337\/db15-0060","article-title":"Genetic Disruption of Protein Kinase STK25 Ameliorates Metabolic Defects in a Diet-Induced Type 2 Diabetes Model","volume":"64","author":"Amrutkar","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2026.103038_bib49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00125-016-4171-5","article-title":"Overexpression of protein kinase STK25 in mice exacerbates ectopic lipid accumulation, mitochondrial dysfunction and insulin resistance in skeletal muscle","volume":"60","author":"Chursa","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2026.103038_bib50","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2026.103038_bib51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2026.103038_bib52","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf314","article-title":"Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement","volume":"46","author":"Romeo","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2026.103038_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/07853890.2014.966752","article-title":"Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study","volume":"47","author":"Suomela","year":"2015","journal-title":"Ann. Med."},{"key":"10.1016\/j.omtn.2026.103038_bib54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s12272-025-01574-w","article-title":"Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials","volume":"48","author":"Liu","year":"2025","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.omtn.2026.103038_bib55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nature04226","article-title":"A haplotype map of the human genome","volume":"437","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103038_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12844-z","article-title":"Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes","volume":"7","author":"Magner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103038_bib57","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2026.103038_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312600209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312600209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:06:05Z","timestamp":1788879965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312600209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S216225312600209X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103038","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An antisense oligonucleotide targeting STK25 as a long-acting therapeutic candidate for early MASLD","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103038"}}